DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the AUROBINDO PHARMA LTD (AUROPHARMA) share price today?

AUROBINDO PHARMA LTD (AUROPHARMA) is trading at ₹1,533.4 on the NSE, down 0.97% on the day. Source: DocStoX.

What is the PE ratio of AUROBINDO PHARMA LTD?

AUROBINDO PHARMA LTD has a price-to-earnings (PE) ratio of 25.4 in the Healthcare sector.

What is the market capitalisation of AUROBINDO PHARMA LTD?

AUROBINDO PHARMA LTD has a market capitalisation of approximately ₹89,061 crore.

AUROBINDO PHARMA LTD

F&O

AUROPHARMA·NSE·Healthcare

₹1,533.40▼ -15.00 (-0.97%)

Healthcare · Pharmaceuticals

A steady, established business

NIFTY 200NIFTY 500NIFTY MIDCAP 150

Day₹1520.40

₹1550.00

52W₹1016

₹163783%

Open

₹1550.00

High

₹1550.00

Low

₹1520.40

Prev Close

₹1548.40

Volume

5.18L

VWAP

₹1533.31

Snapshot

Key fundamentals

Market Cap

₹89,061 Cr

P/E Ratio

25.41Fair

P/B Ratio

2.39

EPS

₹60.34

Book Value

₹652.00

ROE

10.10%Average

ROCE

13.00%Decent

Dividend Yield

0.25%

Debt / Equity

0.21Low

Face Value

₹1.00

52W High

₹1636.80

52W Low

₹1016.10

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatHigh uncertainty

Fair value estimate

₹705

▼ 54.0%downside

Trading at ₹1,533 — 54% above our estimate

BearFair valueBull

₹600₹705₹941

/100

Business quality — Solid

Growth 65Profitability 36Efficiency 13Valuation 75

Plain English

Our view

A steady, established business
Low debt relative to equity
Fundamental red flags (Piotroski 1/9)

Strengths

Low debt relative to equity
Profit growing 22% a year
Promoters hold a controlling stake

Risks

Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

10% ROE fading to 12% over ~3 yrs, on ₹652 book

₹640

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹941

Analyst target

No analyst coverage

—

Blended fair value₹705

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Profit growing 22% a year
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

25.4Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

10.1%Average

Above 15% is considered healthy for Indian equities

ROCE

13.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.21Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹89,061 Cr

P/B

2.39

EPS

₹60.34

Div Yield

0.25%

What changed

Recent changes

Foreign investors+1.1% stake last quarter
Domestic institutions-0.8% stake last quarter
Promoters+0.06% stake last quarter

What matters

News impact

Overview

Valuation

Reasonable

P/E 25.4×

Growth

Steady

+11% rev CAGR

Profitability

Modest

10.1% ROE

Financial health

Rock solid

D/E 0.21

Momentum

N/A

No technicals

Today

Trading activity

Delivery %50.3%

Turnover₹7943.18L Cr

Trades30,084

VWAP₹1533.31

Face value₹1.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+10.6%

+6.3%

10Y

+9.3%

Profit

+22.0%

-8.1%

10Y

+5.6%

EPS

+22.4%

-7.9%

10Y

+5.7%

Profile

Cons

The company has delivered a poor sales growth of 6.32% over past five years.
Company has a low return on equity of 10.8% over last 3 years.
Company might be capitalizing the interest cost

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Promoters raised their stake by 0.06 pts; foreign investors bought 1.14 pts; domestic institutions reduced 0.77 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

52%

Promoter

Promoters

51.9%+0.06

Public

6.6%-0.45

FII / FPI

16.4%+1.14

DII

25.1%-0.77

Quarterly trend

Ownership over time

Q1 FY27

Promoter51.88%

FII16.38%

DII25.05%

Public6.63%

Others0.06%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)

F&O